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Abstract 
Background: The aim of this study was to investigate the expression of the nuclear receptor PPARγ, together with 
that of the cyclooxygenases Cox-1 and Cox-2, in breast cancer (BC) tissues and to correlate the data with several clini-
cobiological parameters including patient survival.
Methods: In a well characterized cohort of 308 primary BC, PPARγ, Cox-1 and Cox-2 cytoplasmic and nuclear expres-
sion were evaluated by immunohistochemistry. Correlations with clinicopathological and aggressiveness features 
were analyzed, as well as survival using Kaplan–Meier analysis.
Results: PPARγ was expressed in almost 58% of the samples with a predominant cytoplasmic location. Cox-1 and 
Cox-2 were exclusively cytoplasmic. Cytoplasmic PPARγ was inversely correlated with nuclear PPARγ and ER expres-
sion, but positively with Cox-1, Cox-2, and other high-risk markers of BC, e.g. HER2, CD133, and N-cadherin. Overall 
survival analysis demonstrated that cytoplasmic PPARγ had a strong correlation with poor survival in the whole 
cohort, and even stronger in the subgroup of patients with no Cox-1 expression where cytoplasmic PPARγ expression 
appeared as an independent marker of poor prognosis. In support of this cross-talk between PPARγ and Cox-1, we 
found that Cox-1 became a marker of good prognosis only when cytoplasmic PPARγ was expressed at high levels.
Conclusion: Altogether, these data suggest that the relative expression of cytoplasmic PPARγ and Cox-1 may play an 
important role in oncogenesis and could be defined as a potential prognosis marker to identify specific high risk BC 
subgroups.
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Background
Breast cancer (BC), the most commonly diagnosed 
malignant tumor in women, is also the most frequent 
cause of cancer death worldwide [1] and a significant 
global public health problem. BC is highly heteroge-
neous in its pathological characteristics, which raised 
a tremendous challenge for treatment selection [2]. 
So far, few biomarkers have been well recognized in 
invasive breast carcinomas, including estrogen recep-
tor (ER) and progesterone receptor (PR), which are 
associated with a better outcome and are predictive of 
endocrine sensitivity. Overexpression of human epi-
dermal growth factor receptor 2 (HER2) is related with 
decreased relapse-free survival (RFS) and overall sur-
vival (OS) [3, 4]. Agents targeting ER and HER2, such as 
tamoxifen and trastuzumab, have been very successful 
as BC therapeutics. However, multifaceted mechanisms 
emerged in tumors, causing resistance to endocrine 
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comprehensive identification of more biomarkers and 
molecular targets is essential for optimal and personal-
ized clinical BC management.
Peroxisome proliferator-activated receptors (PPARs) 
belong to the nuclear receptor (NR) superfamily [6] and 
function as ligand-activated transcription factors [7]. Fol-
lowing activation by ligands (e.g. 15d-PGJ2 or the syn-
thetic ligand thiazolidinedione), PPARs heterodimerize 
with retinoid X receptor (RXR) and interact with pro-
liferator-activated receptor response elements (PPREs) 
present in target gene promoters [8]. Although the NR 
superfamily was defined due to genomic actions of the 
receptors which require nuclear localization, it has been 
suggested that PPARs localize first in the cytoplasm with 
specific associated functions [9].
Among the three PPAR isoforms (α, β/δ and γ), PPARγ 
plays a crucial role in adipogenesis and lipid metabolism 
[10] and is also found expressed in many human cancers, 
including BC [11]. PPARγ influences inflammatory pro-
cesses, cell proliferation, differentiation, apoptosis and 
tumor angiogenesis [10, 12]. A tumor promoting effect of 
PPARγ has been reported in some tumors, such as liver 
[13], cancer [14] or colon cancer [15]. In addition, most 
of previous studies have revealed that PPARγ acts as a 
tumor suppressor in BC, inhibiting cell proliferation and 
inducing apoptosis in different in vivo and in vitro mod-
els [16–18]. Besides, PPARγ has been suggested as being 
involved in chemotherapy resistance of TNBC [19].
Interestingly, some of the PPARγ ligands, prostaglan-
dins (PGs) are produced from the conversion of arachi-
donic acid by the cyclooxygenases Cox-1 and Cox-2. 
Cox-1 is constitutively expressed in many normal cells, 
whereas Cox-2 is generally considered being induced by 
inflammatory cytokines and growth factors, performing 
a significant role in carcinogenesis [20, 21]. Studies of 
Cox importance in tumor progression and invasion were 
mainly focused on the influence of Cox-2 [22]. However, 
it was demonstrated that Cox-1 is highly expressed and 
plays a pivotal role in some carcinomas, such as ovarian 
[23] and breast cancers [24]. More recently, Cox-1 mRNA 
and protein levels have been shown to be higher in malig-
nant breast tumors than in normal tissues, whereas 
Cox-2 mRNA level was lower in malignant tumors. 
Nonetheless, stromal and glandular Cox-2 immunostain-
ing showed higher levels in malignant breast tumors [25].
It appears therefore obvious that more attention is 
needed to analyze the relevance of combined expression 
of PPARγ and Cox (especially Cox-1) in BC. In the pre-
sent study, we have analyzed expression of PPARγ and 
of the two Cox proteins in 308 primary BC specimens 
in relation to survival, to determine if either one could, 




A total of 308 formalin-fixed paraffin-embedded pri-
mary BC tissues from 303 patients (5 of them are bilat-
eral BC) who received surgeries between 2000 and 2002 
at the Department of Obstetrics and Gynecology of the 
Ludwig-Maximilians-University Munich, Germany were 
collected. Local and systemic therapy treatment was 
given according to the guidelines at the time of diagnosis. 
This study was approved by the Ethical Committee of the 
Medical Faculty, Ludwig-Maximilian-University, Munich, 
Germany (approval number 048-08) and informed con-
sent for nuclear factor analysis was obtained from all 
patients who were alive at the time of follow-up. Data, 
such as age, histological grade, metastases, local recur-
rence, progression, and survival were retrieved from the 
Munich Cancer Registry and anonymized and encoded 
during statistical analysis and experiments. All tumors 
were assessed according to UICC TNM classification, 
containing tumor size and extent of tumors (primary 
tumor size, or pT, classified as: pT1a-c, pT2, pT3, pT4a-
d), lymph node status (N), and presence or absence of 
metastasis (M). Tumor grade was determined by an expe-
rienced pathologist (Dr. D. Mayr) of the Department of 
Pathology of the LMU, according to a modification of 
Elston and Ellis grading proposed by Bloom and Richard-
son [26]. Sixty (19.48%) of the 303 primary BC patients, 
became metastatic during the follow-up. ER, PR, HER2, 
Ki-67 and histological status were all determined by an 
experienced pathologist of the LMU Department of 
Pathology, as described below. HER2 2+ scores were fur-
ther evaluated through fluorescence in situ hybridization 
(FISH) testing.
Immunohistochemistry (IHC)
Expression of ERα, PR, and HER2 was determined at 
diagnosis in all BC samples of this cohort at the LMU 
Department of Pathology, Germany. ERα and PR expres-
sion were evaluated by immunohistochemistry, as 
described previously [26]. Samples showing nuclear 
staining in more than 10% of tumor cells were consid-
ered as hormone receptor-positive, in agreement with 
the guidelines at the time of the analysis (2000–2002). 
HER2 expression was analyzed using an automated 
staining system (Ventana; Roche, Mannheim, Ger-
many), according to the manufacturer’s instructions. 
Ki-67 was stained using an anti-Ki67 monoclonal anti-
body (Dako, Hamburg, Germany) at a dilution of 1:150 
on a  VENTANA®-Benchmark Unit (Roche, Mannheim, 
Germany) as previously described [27]. The Ki-67 cut-off 
used to differentiate luminal A from luminal B tumors 
(all HER2 negative) was 14% as this was commonly used 
at the time of the analysis, although 20% is now preferred 
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[28]. Data on N-cadherin and CD133 expression in these 
BC samples were extracted from a previously published 
study [29]. For PPARγ, Cox-1 and Cox-2 analysis by IHC, 
samples were processed as previously described [30, 31]. 
Briefly, sections were first cut and prepared from par-
affin-embedded BC samples using standard protocols. 
Phosphate buffered saline (PBS) was used for all washes 
and sections were incubated in blocking solution (Zyto-
Chem Plus HRP Polymer System Kit, ZYTOMED Sys-
tems GmbH, Berlin, Germany) before incubation with 
primary antibodies. All primary antibodies were rabbit 
IgG polyclonal used at a 1:100 dilution for 16 h at 4  °C: 
anti-PPARγ (ab59256, Abcam, Cambridge, UK) or anti-
Cox-1 (HPA002834) and anti-Cox-2 (SAB4502491, both 
Sigma-Aldrich, Saint Louis, MO, USA). After incubation 
with a biotinylated secondary anti-rabbit IgG antibody, 
and with the associated avidin–biotin–peroxidase-com-
plex (both Vectastain Elite ABC Kit; Vector Laborato-
ries, Burlingame, CA, USA), visualization was performed 
with substrate and chromogen 3,3-diamino-benzidine 
(DAB; Dako, Glostrup, Denmark). Negative and positive 
controls were used to assess the specificity of the immu-
noreactions. Negative controls (colored in blue) were 
performed in BC tissue by replacement of the primary 
antibodies by species-specific (rabbit) isotype control 
antibodies (Dako, Glostrup, Denmark). Appropriate posi-
tive controls (placenta samples) were included in each 
experiment. Sections were counterstained with acidic 
hematoxylin, dehydrated and immediately mounted with 
Eukitt (Merck, Darmstadt, Germany) before manual 
analysis with a Diaplan light microscope (Leitz, Wet-
zlar, Germany) with 25× magnification. Pictures were 
obtained with a digital CCD camera system (JVC, Tokyo, 
Japan). All slides were analyzed by two or three inde-
pendent examiners.
Immunoreactive score (IRS)
The expression of PPARγ, Cox-1 and Cox-2 was assessed 
according to the immunoreactive score (IRS), deter-
mined by evaluating the proportion of positive tumor 
cells, scored as 0 (no staining), 1 (≤ 10% of stained cells), 
2 (11–50% of stained cells), 3 (51–80% of stained cells) 
and 4 (≥ 80% of stained cells), and the intensity of their 
staining, graded as 0 (negative), 1 (weak), 2 (moderate) 
and 3 (strong) (IRS = percentage score × intensity score). 
Thus, the range of IRS value is from 0 to 12. As previ-
ously described for LCoR and RIP140 [31] and for AhR 
[32], PPARγ cytoplasmic and nuclear staining were eval-
uated in parallel, with a separate determination of cyto-
plasmic IRS and nuclear IRS. Total IRS was calculated 
by addition of cytoplasmic and nuclear IRS. For all other 
markers, staining and IRS were determined in the whole 
cells, without differentiation of nuclear and cytoplasmic 
staining.
Survival and statistical analysis
Receiver operating characteristic curve (ROC) analyses 
were performed to calculate the optimal cut-off values 
between low and high PPARγ, Cox-1 and Cox-2 expres-
sions, based upon the maximal differences of sensitivity 
and specificity. The threshold determined regarding OS 
were an IRS ≥ 3.5 for either total or cytoplasmic PPARγ, 
≥ 0.5 for nuclear PPARγ and for Cox-1, and finally ≥ 1.5 
for Cox-2. These thresholds were used to determine the 
percentages of tumors expressing low or high PPARγ, 
Cox-1 and Cox-2 levels described in Table 2, besides the 
OS analysis detailed below. To present the mean immu-
noreactivity levels described by the IRS in Table  2, the 
groups were divided into low- vs. high-expressing cases 
for total and cytoplasmic PPARγ, Cox-2, or into not 
expressing vs. expressing cases for nuclear PPARγ, Cox-1 
(cut-off values of 0.5).
Differences in nuclear PPARγ expression among three 
or more groups (Fig.  1, panel k) were tested using the 
non-parametric Kruskal–Wallis rank-sum test. Correla-
tion analyses presented in Tables 3 and 4 were performed 
by calculating the Spearman’s-Rho correlation coefficient 
(p values of Spearman’s-Rho test presented). Survival 
times were compared by Kaplan–Meier graphics and dif-
ferences in OS (or RFS) were tested for significance by 
using the Chi-square statistics of the log rank test. Data 
were assumed to be statistically significant in the case of 
p-value < 0.05. Kaplan–Meier curves and estimates were 
then provided for each subgroup and each marker. The p 
value and the number of patients analyzed in each sub-
group are given for each chart.
Multivariable analysis for outcome (OS) presented in 
Table 5 was performed using the Cox regression model, 
and included cytoplasmic PPARγ expression and relevant 
clinicopathological characteristics as independent varia-
bles. Variables were selected based on theoretical consid-
erations and forced into the model. p values and hazard 
ratios were indicated, knowing that the hazard ratios of 
covariates are interpretable as multiplicative effects on 
the hazard, and holding the other covariates constant.
Statistical analyses were performed using SPSS 24 
(IBMSPSS Statistics, IBM Corp., Armonk, NY, USA). 
For all analyses, p values below 0.05 (*), 0.01 (**), or 0.001 
(***) were considered statistically significant.
Results
PPARγ and Cox expression in breast cancers
The total cohort consisted of 308 samples from 303 
primary BC (Table  1). Median age of initial diagnosis 
was 57.98 years (range 26.66–94.62 years) and median 
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follow-up time was 125 months (range 0–153 months). 
During this period, 41 (13.3%) and 60 (19.5%) cases 
experienced local recurrence and distant metastasis 
respectively, and 90 (29.2%) women died.
The expression of PPARγ, Cox-1 and Cox-2 was 
analyzed by IHC staining, as illustrated in Fig.  1 for 3 
patients with Grade 1 (A, B, C), 2 (D, E, F) and 3 (G, H, 
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Fig. 1 Immunohistochemical stainings of PPARγ, Cox-1 and Cox-2 expression in breast carcinoma of 3 patients and a box-plot of nuclear PPARγ and 
Grading. PPARγ (a, d, g), Cox-1 (b, e, h) and Cox-2 (c, f, i) stainings are illustrated for patients with different grading (Grade 1 in a–c, 2 in d–f and 3 in 
g–i), with examples of null, average or high expressions. Nucleo:cytoplasmic IRS ratios are indicated in each photomicrograph (×25 magnification) 
and scale bar equals 100 μm. An enlargement of g (high cytoplasmic and null nuclear PPARγ staining) is presented (j) and scale bar equals 50 μm. 
Correlation between nuclear PPARγ and grading was presented as box plot (k). The boxes represent the range between the 25th and 75th 
percentiles with a horizontal line at the median. The bars on top and below depict the 5th and 95th percentiles. Values more than 1.5 box lengths 
from the 75th percentile are indicated by circles (none) and values more than 3.0 box lengths from the 75th percentile are indicated by asterisks. 
The numbers on asterisks represent the case number. Statistical significance is shown as p-value from Kruskal–Wallis test (**p < 0.01)
Page 5 of 14Shao et al. J Transl Med           (2020) 18:94  
in the nucleus and in the cytoplasm, while Cox-1 and 
Cox-2 (B, E, H, and C, F, I respectively) were exclusively 
cytoplasmic. The nucleo:cytoplasmic IRS ratios are pre-
sented in each panel (panel J shows the enlargement of 
PPARγ staining shown in panel G). From now, all Cox-1 
and Cox-2 expression refers to their unique cytoplas-
mic expression, with Cox-1 staining being much fainter 
than Cox-2 staining, as described in Table  2. As dem-
onstrated in the panel K, nuclear PPARγ exhibited a 
statistically different expression according to grading, 
with an inverted correlation (p = 0.002). This correla-
tion is illustrated by focusing on the nuclear PPARγ 
expression observed in panels A, D and G of Fig. 1 (IRS 
of 2, 0 and 0 respectively) for patients with respectively 
grade 1, 2 and 3 tumors.
As presented in Table  2, the mean IRS of total and 
cytoplasmic PPARγ expression were 4.37 and 4.09 
respectively, while it was 0.27 for nuclear PPARγ. It 
clearly appears that, in our cohort, PPARγ expression is 
dramatically higher (15-fold) in the cytoplasm than in 
the nucleus, with maximal IRS values of 12 and 4 respec-
tively. This is exemplified in Fig.  1 with cytoplasmic 
PPARγ IRS values of 1, 6 and 9, and nuclear PPARγ IRS 
values of 0 and 2 (panels A, D and J). IRS cut-offs were 
defined by performing a ROC-curve analysis for OS. Of 
note, the IRS cut-off of 0.5 generated for nuclear PPARγ 
staining is related to the low expression level of this 
marker in our cohort, and create sub-groups with nega-
tive vs. positive expression, instead of low vs. high expres-
sion for other cut-off values. Considering cytoplasmic or 
total expression of PPARγ being high for IRS value > 3.5, 
the high expression group is predominant in both cases 
(52.7 and 57.6% respectively). Only 20 patients out of 262 
(7.6%) had no cytoplasmic PPARγ expression (IRS = 0), 
demonstrating the predominant cytoplasmic expression 
of PPARγ (92.4% of the tumors).




N = 308b %
Age, median (years) 57.98
Follow up, average (months) 109.89
Median 125
Histologyc
 Invasive lobular 41 13.31
 Invasive medullar 10 3.25
 Invasive mucinous 3 0.97
 No special type (NST) 161 52.27
 DCIS with NST 78 25.33
 Unknown 15 4.87
ER status
 Positive 248 80.52
 Negative 58 18.83
 Unknown 2 0.65
PR status
 Positive 178 57.79
 Negative 128 41.56
 Unknown 2 0.65
HER2 status
 Positive 35 11.36
 Negative 271 87.99
 Unknown 2 0.65
Molecular subtype
 Luminal A (Ki-67 ≤ 14%) 170 55.19
 Luminal B (Ki-67 > 14%) 63 20.45
 HER2 positive luminal 27 8.77
 HER2 positive non luminal 8 2.60
 Triple negative 38 12.34
 Unknown 2 0.65
Grade
 I 15 4.87
 II 102 33.12
 III 45 14.61
 Unknown 146 47.40
Tumor size
 pT1 191 62.01
 pT2 87 28.25
 pT3 4 1.30
 pT4 12 3.90
 Unknown 14 4.55
Lymph node metastasis
 Yes 126 40.91
 No 163 52.92
 Unknown 19 6.17
Local  recurrenced
 Yes 41 13.31
 No 253 82.14
 Unknown 14 4.55
a All information given refer to the primary tumor
b 5 of 303 patients are bilateral primary BC, so we deal with the tumor as 
individual one (n = 308)
c NST include the formerly called “Invasive ductal” and “other” types
d Local recurrence has been detected during the follow-up of 40 patients (1 of 
them are bilateral BC, so n = 41)
e Distant metastasis has been detected during the follow-up of 58 patients (2 of 




N = 308b %
Distant  metastasese
 Yes 60 19.48
 No 234 75.97
 Unknown 14 4.55
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Besides, the mean IRS of cytoplasmic expression were 
0.34 and 5.19 for Cox-1 and Cox-2 respectively. This is 
again exemplified in Fig. 1 with Cox-1 IRS values of 0 and 
2 (panels B, E and H) and Cox-2 IRS values of 4, 6 and 9 
(panels C, F and I), for the same 3 selected patients. Simi-
larly to nuclear PPARγ, Cox-1 mean IRS being very low, a 
cut-off of 0.5 was generated, with sub-groups of negative 
vs. positive expression, instead of low vs. high expression 
for Cox-2. In our cohort, 75.4% of the samples were then 
Cox-1 negative, whereas the samples with a high expres-
sion of Cox-2 represented 87.37% of the cases (cut-off 
of 1.5). Regarding nuclear PPARγ, only 49 samples were 
positive (18.7%) while for Cox-1, only 73 samples (24.6%) 
were positive (with maximum IRS of 4 for both markers).
Correlation between PPARγ and Cox expression
The correlations between the expression levels of PPARγ 
(total, nuclear and cytoplasmic), Cox-1 and Cox-2 were 
analyzed (Table 3). Cytoplasmic PPARγ expression exhib-
ited a strong and significant positive correlation with 
total PPARγ, and a negative one with nuclear PPARγ. By 
Table 2 Distribution of expression of PPARγ, Cox-1 and Cox-2
IRS cut-offs were defined by performing a ROC-curve analysis for DFS. The cut-off of 0.5 for nuclear PPARγ and for Cox-1 stainings, related to the low expression level 
of both markers in our cohort, define negative and positive expressions, instead of low and high expressions sub-groups respectively
PPARγ Cox-1 Cox-2
Total Nuclear Cytoplasmic
n 262 262 262 297 285
Mean IRS ± SE 4.37 ± 0.17 0.27 ± 0.04 4.09 ± 0.17 0.34 ± 0.04 5.19 ± 0.19
IRS range 12 4 12 4 12
IRS cut-off 3.5 0.5 3.5 0.5 1.5
Number of samples with 
negative/low expression
111 (42.4%) 213 (81.3%) 124 (47.3%) 224 (75.4%) 36 (12.6%)
Number of samples with 
positive/high expression
151 (57.6%) 49 (18.7%) 138 (52.7%) 73 (24.6%) 249 (87.4%)
Table 3 Correlation between  PPARγ, Cox-1 and  Cox-2 
expression
Correlations are statistically significant for p < 0.05 (*) or p < 0.01 (**), using 
Spearman-Rho-Test




 Nuclear 0.037 1.000
 Cytoplasmic 0.959** − 0.215** 1.000
 Cox-1 0.179** − 0.117 0.201** 1.000
 Cox-2 0.261** − 0.124* 0.293** 0.054 1.000
Table 4 Correlation between  PPARγ, Cox-1 and  Cox-2 expression and  clinicopathological or  aggressiveness related 
parameters
Correlations are statistically significant for p < 0.05 (*) or p < 0.01 (**), using Spearman-Rho-Test
PPARγ n = 143 to 262 Cox-1 Cox-2
Total Nuclear Cytoplasmic n = 159 to 297 n = 153 to 285
Age 0.004 − 0.050 0.002 0.041 − 0.015
pT 0.118 − 0.037 0.113 − 0.049 − 0.066
pN 0.069 0.023 0.065 − 0.125* − 0.043
Grade 0.007 − 0.205* 0.054 − 0.007 − 0.062
ER − 0.119 0.117 − 0.142* 0.009 0.039
PR − 0.048 0.038 − 0.049 − 0.018 0.012
HER2 0.157** − 0.127* 0.173** 0.137* 0.090
Triple negative 0.076 − 0.062 0.085 − 0.043 − 0.052
Ki-67 0.116 − 0.039 0.119 0.084 0.155*
Focality 0.043 0.074 0.016 − 0.048 − 0.028
CD133 0.221** − 0.007 0.230** 0.132* 0.378**
NCAD 0.412** − 0.196** 0.447** 0.241** 0.461**
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contrast, nuclear and total expression of PPARγ were not 
correlated together. Regarding Cox expression, Cox-1 
and Cox-2 levels were not correlated. Nonetheless, both 
Cox-1 and Cox-2 expression were significantly correlated 
with cytoplasmic and total PPARγ expressions. Besides, 
nuclear PPARγ was significantly negatively correlated 
with Cox-2 (and not with Cox-1).
Correlation between PPARγ, Cox expression 
and clinicopathological parameters or aggressiveness 
markers
We then analyzed the correlations between PPARγ or 
Cox expression and known clinicopathological char-
acteristics (Table  4). We also quantified the expression 
of two aggressiveness markers, CD133, a widely used 
marker for isolating cancer stem cell (CSC) [33, 34], 
and N-cadherin, a well-known marker for epithelial-to-
mesenchymal transition (EMT) [35]. Considering first 
nuclear PPARγ, significant negative correlations were 
observed with grade (as already illustrated in Fig. 1k, and 
by the 3 selected patients in Fig.  1), HER2 and N-cad-
herin, as well as Cox-2 (as already shown in Table 3). On 
the contrary, total and cytoplasmic PPARγ were strongly 
positively correlated with HER2, CD133 and N-cadherin. 
Only cytoplasmic PPARγ was negatively correlated to 
ER. Besides, Cox-1 was positively correlated with HER2, 
CD133, and N-cadherin, while Cox-2 was positively cor-
related with Ki-67, CD133, and N-cadherin. Only Cox-1 
was statistically negatively correlated with lymph node 
status (LNM), and only Cox-2 was positively correlated 
with the proliferation marker Ki-67.
Correlation between PPARγ, Cox expression, and patient 
survival
In order to analyze the correlation between PPARγ and 
survival, we performed Kaplan–Meier analyses. We used 
the cut-off IRS values determined by ROC-curve analysis, 
allowing the maximal difference of sensitivity and speci-
ficity (as described in Table 2). In Fig. 2, considering the 
OS of the whole cohort, the cytoplasmic PPARγ expres-
sion was able to discriminate high expressing tumors 
with a significantly worse survival than patients with low 
expressing tumors (mean OS: 10.55  years vs 9.44  years, 
p = 0.027; Fig.  2a). On the contrary, neither nuclear 
PPARγ (Fig. 2b) nor total PPARγ (Additional file 1: Fig-
ure S1A) had any significant correlation with OS.
RFS analysis were performed in parallel for total, cyto-
plasmic and nuclear PPARγ expression (Additional file 1: 
Figure  S1B–D respectively). Both total and cytoplasmic 
PPARγ significantly discriminated patients with worse 
RFS (when PPARγ was highly expressed) from those 
having better survival when PPARγ expression was low 
(mean RFS: 9.37 years vs 6.88 years, p = 0.001, and mean 
RFS: 9.30 years vs 6.70 years, p = 0.000217).
We then looked at the association between cytoplas-
mic PPARγ expression and OS in different subgroups 
by stratifying the cohort, according to parameters men-
tioned in Table 4. Compared to the correlation of cyto-
plasmic PPARγ expression with OS in the whole cohort 
(p = 0.027, Fig.  2a), the correlation was stronger in the 
subgroup of luminal A tumors (p = 0.005 Fig. 2c), and lost 
in the luminal B subgroup (Fig. 2d). Similarly, the correla-
tion was very strong in the subgroup of N-Cadherin low 
expressing tumors (p = 0.007, Fig.  2e) and absent in the 
N-Cadherin high expressing tumors (Fig. 2f ).
We then focused on subgroups of patients according 
to Cox expression in their tumors. As demonstrated in 
Fig. 3, expression of cytoplasmic PPARγ was still clearly 
related to a worse prognosis in the subgroup of tumors 
expressing no Cox-1 (p = 0.001, Fig.  3a), as observed in 
the whole cohort (p = 0.027, Fig.  2a). On the contrary, 
no correlation of cytoplasmic PPARγ existed with the 
OS of patients with tumor expressing Cox-1, and the 
trend, although not significant, was even inverted with an 
apparently better prognosis for group with high cytoplas-
mic PPARγ expression (Fig. 3b).
In the subgroup of patients with low Cox-2 expres-
sion (using a cut-off IRS of 7), expression of cytoplasmic 
PPARγ was still related to a poor prognosis (p = 0.009, 
Fig.  3c) while no correlation of cytoplasmic PPARγ and 
OS existed for the patients with high Cox-2 expression 
(Fig. 3d).
Cytoplasmic PPARγ expression as an independent 
prognostic parameter of OS in N-cadherin low and Cox-1 
negative tumors
We then performed multivariate analyses for the whole 
cohort and for the subgroups of patients described above, 
using the Cox regression model with cytoplasmic PPARγ 
expression and various clinicopathological features (age 
at time of diagnosis, tumor size, ER, and HER2 status). 
As shown in Table 5, data demonstrated that in the whole 
cohort, only age, tumor size and ER were independ-
ent prognostic markers of OS. Very interestingly, cyto-
plasmic PPARγ appeared as an independent prognosis 
marker in the N-cadherin low (IRS < 3.5) and Cox-1 nega-
tive subgroups (p = 0.044 and p = 0.014 respectively), 
with hazard ratios of 1.996 and 2.047 indicating a much 
higher risk of death for the patients with tumors express-
ing high levels of cytoplasmic PPARγ.
On the opposite, cytoplasmic PPARγ had no independ-
ent prognostic value in the N-cadherin high or Cox-1 
positive expressing subgroups, in the subgroups with low 
or high Cox-2 expression (IRS cut-off of 7) or even in the 
Luminal A subgroup (data not shown). The same analysis 





















































































Fig. 2 Kaplan–Meier analysis of patient overall survival according to nuclear and cytoplasmic PPARγ expression in the whole cohort, and to 
cytoplasmic PPARγ expression in subgroups. In the whole cohort, overall survival (OS) curves are presented according to cytoplasmic PPARγ (a) and 
nuclear PPARγ (b) status. In luminal (c, d) and N-Cadherin (e, f) subgroups, overall survival curves are presented according to cytoplasmic PPARγ 
status. The IRS cut-off values with the number of cases for each group are indicated in each graph. Statistical significance is shown as p-value from 
log-rank test (*p < 0.05; **p < 0.01)
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Fig. 3 Kaplan–Meier analysis of patient overall survival according to cytoplasmic PPARγ and of Cox-1 expression in subgroups. Overall survival (OS) 
curves are presented according to cytoplasmic PPARγ status in Cox-1 (a, b) and Cox-2 (c, d) subgroups. OS of Cox-1 is then presented according to 
cytoplasmic PPARγ (e, f). The IRS cut-off values with the number of cases for each group are indicated in each graph. Statistical significance is shown 
as p-value from log-rank test (*p < 0.05; **p < 0.01)
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performed with nuclear or total PPARγ, with Cox-1 or 
Cox-2, did not reveal any independent prognostic value 
as seen with cytoplasmic PPARγ.
Cox-1 expression is associated with favorable OS 
only in tumors with high cytoplasmic PPARγ expression
We then checked in the whole cohort that neither Cox-1 
nor Cox-2 expression was related to OS (Additional file 1: 
Figure  S2A, B respectively). In order to strengthen the 
link between PPARγ, Cox1, and survival, we analyzed 
the prognostic value of Cox1 according to PPARγ lev-
els. By selecting patients with tumors expressing high 
levels of cytoplasmic PPARγ (Fig.  3f ), Cox-1 expres-
sion appeared statistically correlated to a better OS of 
patients (p = 0.032). For patients with tumors expressing 
low levels of cytoplasmic PPARγ (Fig. 3e), no correlation 
with OS appeared although we observed again an oppo-
site trend, with Cox-1 expression numerically correlated 
with a poor OS. Altogether, these data strengthened 
our results demonstrating that the relative expression 
of cytoplasmic PPARγ and Cox-1 is linked to prognosis 
in primary BC, with a high cytoplasmic PPARγ/Cox-1 
ratio being a marker for poor prognosis, and that Cox-1 
expression correlated with longer OS in an unselected 
cohort.
Discussion
The aim of this study was to characterize the intracel-
lular expression and possible interplay of PPARγ and 
the Cox (Cox-1 and Cox-2) expression in a wide range 
of BC specimens, in relation with the clinicopathologi-
cal parameters as well as patient survival. We already 
demonstrated that cytoplasmic PPARγ is overexpressed 
in BRCA1 mutated BC compared to sporadic cases, but 
without correlation to survival [27]. In previous surveys, 
either nuclear PPARγ or cytoplasmic PPARγ had a corre-
lation with an improved clinical outcome of BC patients 
[8, 36, 37], but fewer specific subgroups of patients were 
analyzed.
Our data demonstrated that PPARγ expression was 
detected in a majority of BC tissues and that it is pre-
dominantly localized in cytoplasm (92.3% vs 18.7%). This 
is in accordance with previous studies [8, 27, 38]. How-
ever, positive PPARγ immunoreactivity was previously 
described as mainly nuclear in normal cells from benign 
samples; in malignant cells, a decreased expression was 
shown which was related to a favorable survival for 
patients [37, 39]. In addition, it was demonstrated that 
casein-kinase-II-dependent phosphorylation of PPARγ 
leads to subcellular translocation of PPARγ from cyto-
plasm to nucleus regulated by CRM1 and that urokinase-
type plasminogen activator promoted atherogenesis in 
hepatocytes by downregulating PON1 gene expression 
via PPARγ nuclear export mechanism [9, 40]. Intracel-
lular distribution of PPARγ was observed in BC tissues 
and cell lines [41], suggesting that poorly differentiated 
samples and highly invasive cell lines displayed mainly 
cytoplasmic PPARγ expression. Moreover, cytoplasmic 
localization of PPARγ was described as being mediated 
by Skp2 upon MEK1-dependent mechanism indicating 
cytoplasmic translocation of PPARγ promoted tumori-
genesis in BC. In another study [17], α-ESA, considered 
as a PPARγ agonist like rosiglitazone, as well as GLA 
[38], suppressed cell growth in BC cell lines by activat-
ing PPARγ nuclear compartmentalization, which sug-
gested that nuclear localization of PPARγ plays a role in 
anti-cancer functions in BC. Besides the predominant 
cytoplasmic localization of PPARγ, our data demonstrate 
a significant correlation between total and cytoplasmic 
PPARγ and an inverse relationship between cytoplasmic 
and nuclear PPARγ (Table 3), supporting the hypothesis 
of the translocation mechanism of PPARγ in the carcino-
genic process.
Table 5 Multivariate analysis of  significant 
clinicopathological variables and  of  cytoplasmic 
PPARγ regarding  OS in  the  whole cohort and  in  various 
subgroups
HR, hazard ratio; p, p-value
In the sub-groups, the same cut-off as in Figs. 2 and 3 have been used, namely 
3.5 for N-Cadherin and 7 for Cox-2. Correlations are statistically significant for 
p < 0.05 (*) or p < 0.01 (**), p < 0.001 (***)
Age pT ER HER2 Cytoplasmic 
PPARγ
Whole cohort
 p 0.00001*** 0.00000007*** 0.008** 0.154 0.129
 HR 1.040 3.769 0.508 1.616 1.457
N-cadherin low
 p 0.002** 0.00037*** 0.015* 0.528 0.044*
 HR 1.041 3.370 0.420 1.341 1.996
N-cadherin high
 p 0.000733*** 0.000032*** 0.174 0.035* 0.902
 HR 1.045 6.121 0.583 3.437 1.052
Cox-1 negative
 p 0.000023*** 0.000008*** 0.162 0.307 0.014*
 HR 1.045 3.835 0.655 1.598 2.047
Cox-1 positive
 p 0.017* 0.017* 0.023* 0.253 0.454
 HR 1.051 3.574 0.284 1.907 0.670
Cox-2 low
 p 0.000002*** 0.00008*** 0.015* 0.969 0.102
 HR 1.058 3.272 0.440 0.983 1.665
Cox-2 high
 p 0.112 0.000343** 0.801 0.021* 0.545
 HR 1.027 7.681 0.867 5.369 1.427
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Concerning the correlation between PPARγ expression 
and clinicopathological features or aggressiveness mark-
ers, our data demonstrated that nuclear PPARγ expres-
sion was inversely correlated with tumor grade, HER2 
and N-cadherin expression, whereas total and cytoplas-
mic PPARγ were positively related with HER2, CD133, 
and N-cadherin (Fig.  1 and Table  4). These correlations 
strongly suggest that only cytoplasmic PPARγ was associ-
ated with the more aggressive tumors, namely ER nega-
tive, HER2 positive, CD133 (as a CSC marker [33, 34]) 
positive and NCAD (as an EMT marker [35]) positive 
sub-groups. Nonetheless, cytoplasmic PPARγ expres-
sion being much higher (15 fold) than nuclear one, total 
PPARγ expression exhibited similar association as cyto-
plasmic one with tumor aggressiveness. Several authors 
also found, as we did, a negative correlation between 
nuclear PPARγ and histological grade [36, 37, 39], and 
one paper indicated that nuclear PPARγ was negatively 
associated with HER2 [39]. Interestingly, PPARγ pro-
tein was expressed in both transfected MCF-7/Neo and 
MCF-7/HER2, but with higher levels of expression in the 
MCF-7/HER2 cells [42]. Moreover, HER2 up-regulated 
PPARγ expression, causing BC cells to become resistant 
to PPARγ ligand response [43]. Both CD133 and N-cad-
herin play a critical role in cancer migratory and invasive 
properties. Indomethacin could decrease CD133 expres-
sion, which means reducing CSCs via inhibiting Cox-2 
and NOTCH/HES1 and activating PPARγ [44]. Accord-
ing to our previous work [29], N-cadherin-positive 
tumors without LNM had a significantly shorter survival 
time. Enhanced activity of PPARγ had an inhibition on 
TGF-β induction of N-cadherin promoter in lung carci-
noma cell lines [45].
Overall, nuclear PPARγ possess a possible protec-
tive role against BC development, whereas cytoplasmic 
PPARγ was defined as a promoter during BC progres-
sion. Our data emphasize this hypothesis of opposite cor-
relation of nuclear PPARγ with antioncogenic parameters 
and of cytoplasmic PPARγ with oncogenic or aggressive 
parameters. Survival analysis in the whole cohort dem-
onstrated that only cytoplasmic PPARγ expression had 
a strong correlation with poor OS (Fig. 2), whereas both 
total and cytoplasmic PPARγ expression had a strong 
correlation with poor RFS (Additional file 1: Figure S1). 
As described earlier, PPARγ activation has been shown 
to exert antiproliferative and pro-apoptotic effects in 
BC cell lines [16–18, 46]. Moreover, cell death has been 
shown to be triggered in BC cell lines through the locali-
zation of PPARγ into the nucleus followed by the induc-
tion of Fas ligand [19]. The analysis of apoptosis markers 
will be necessary to give more insight in the molecular 
mechanisms underlying the differential effects of cyto-
plasmic and nuclear PPARγ.
Analysis of Cox in our cohort of primary BC substanti-
ated that both Cox-1 and Cox-2 were dominantly local-
ized in cytoplasm with a predominant negative or low 
expression for Cox-1 and a high expression for Cox-2 
(Table  2). However, they were both significantly and 
positively correlated with total and cytoplasmic PPARγ, 
whereas only Cox-2 expression was negatively correlated 
with nuclear PPARγ (Table  3). Additionally, similarly to 
cytoplasmic PPARγ, Cox-1 was positively associated 
with HER2, CD133, and N-cadherin. Nonetheless, it was 
inversely related to LN involvement (Table 4), suggesting 
the hypothesis that Cox-1 expression may be related to 
the evolution of the tumor, especially expressed during 
the early non-metastatic stages of BC. Moreover, Cox-2 
was positively related to Ki-67, CD133, and N-cadherin. 
In breast CSCs deprived from tumor cells of HER2/Neu 
mice, both Cox-1 and Cox-2 genes, belonging to a set of 
genes representing possible molecular targets correlated 
with BC survival, are overexpressed [47]. Compared to 
Cox-2, less attention was paid to Cox-1 in tumors and 
fewer data elucidated that Cox-1 selective inhibitors, 
such as SC-560 [48], catechin [49] and FR122047 [50], 
suppressed cell growth in BC. More interestingly, corti-
cotropin-releasing factor, a hypothalamic neuropeptide, 
promoted cell invasiveness in MCF-7 BC cell line via 
induction of Cox-1 expression but not of Cox-2, as well 
as the production of prostaglandins [51].
Cox was officially known as an enzyme responsible for 
the synthesis of PGs from arachidonic acid. The role of 
Cox-2 and PPARγ in pro-apoptosis and tumor regres-
sion was explored in lung cancer cell lines, demonstrat-
ing that cannabidiol induced the upregulation of Cox-2 
and PPARγ following a nuclear translocation of PPARγ 
by Cox-2 dependent PGs [52]. Modulation of 15d-PGJ2, 
a natural ligand of PPARγ, may influence the develop-
ment of BC progress [53]. Cox-1 could lead to the activa-
tion of PPARγ [54]. Our finding of a strong correlation 
between Cox-1 and cytoplasmic PPARγ highlight their 
possible interaction in BC cells. Furthermore, Cox-1 and 
Cox-2 expression has been shown to be strongly associ-
ated in BC to the expression of the aromatase (CYP19A1) 
[55] which has been shown to be associated with a poor 
survival of ER positive BC patients [56]. As a conse-
quence, the link of cytoplasmic PPARγ with poor survival 
might involve the dysregulation of CYP19A1 expres-
sion through Cox activity. Obviously, other mechanisms 
might participate and further work will be needed to 
decipher the precise underlying mechanisms.
In our study, although neither Cox-1 nor Cox-2 were 
related to OS in the whole cohort (Additional file 1: Fig-
ure  S2A, B), high cytoplasmic PPARγ expression was 
significantly associated with poor OS in the Cox-1 nega-
tive subgroup and in the Cox-2 low expression subgroup 
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(Fig. 3a, c). In addition, we also observed that the trend 
was inverted with an apparent, although not significant, 
better prognosis for the patients with high cytoplas-
mic PPARγ expression in the Cox-1 positive subgroup. 
Moreover, the data we generated demonstrate that cyto-
plasmic PPARγ expression is an independent prognos-
tic marker in the Cox-1 negative subgroups, related to a 
twofold higher risk of death for those patients. Interest-
ingly, positive Cox-1 expression (inversely related to the 
LN status) was defined as a favorable outcome marker 
for the patients with high cytoplasmic PPARγ expression 
(Fig. 3f ), and tended to be a bad outcome marker for the 
patients with low cytoplasmic PPARγ expression. Our 
data suggest that the expression of Cox-1 and cytoplas-
mic PPARγ are interdependent, with the ability for Cox-1 
to rescue the negative impact of cytoplasmic PPARγ on 
patient outcome. A hypothesis could be a potential role 
of Cox-1 in nucleocytoplasmic translocation of PPARγ, 
thereby suppressing tumor growth.
Conclusions
In our primary BC cohort, PPARγ was predominantly 
expressed in cytoplasm of BC cells and may perform dif-
ferent roles in tumorigenesis according to its subcellular 
localization. Cytoplasmic PPARγ was strongly correlated 
with Cox-1 mainly, as well as with other bad prognosis 
markers (HER2, CD133, N-cadherin), contributing to 
explore their interactions during BC progression. High 
cytoplasmic PPARγ expression was correlated with short 
OS in the whole cohort and in several subgroups with 
good prognosis. A major conclusion is that this bad prog-
nostic impact of cytoplasmic PPARγ depends on Cox-1 
expression, as it is worse when Cox-1 is negative and lost 
when Cox-1 is expressed. Altogether, this leads to the 
strengthening that the intracellular PPARγ localization 
might be involved in tumorigenesis, and to the conclu-
sion that cytoplasmic PPARγ may be defined as a poten-
tial therapeutic target and a prognostic marker in BC. 
Further analyses are now needed to decipher the molecu-
lar mechanisms underlying PPARγ interplay with Cox-1 
and Cox-2 to modulate BC aggressiveness through the 
control of cell proliferation and/or apoptosis.
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